Welcome to our dedicated page for Aptorum Group news (Ticker: APM), a resource for investors and traders seeking the latest updates and insights on Aptorum Group stock.
Aptorum Group Limited (NASDAQ: APM) is described in its public communications as a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapeutic assets for diseases with unmet medical needs, particularly in oncology, including orphan oncology indications, and infectious diseases. The company’s news flow also reflects its involvement in healthcare services and diagnostics collaborations, such as the co-development of the PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology.
Recent Aptorum news has highlighted a series of significant corporate and strategic developments. A central theme is the proposed all-stock merger with DiamiR Biosciences Corp., a molecular diagnostics company focused on minimally invasive tests for brain health and other diseases. Multiple joint press releases describe the Agreement and Plan of Merger, the expected ownership split between Aptorum shareholders and DiamiR stockholders, and the intention for DiamiR to become a wholly owned subsidiary of Aptorum, subject to shareholder approvals and customary closing conditions.
News items also cover DiamiR’s activities that are relevant to the combined story, including acceptance of scientific abstracts at the Clinical Trials on Alzheimer’s Disease (CTAD) conference and regulatory milestones such as New York State approval for DiamiR’s APOE genotyping test. These updates emphasize DiamiR’s CLIA-certified, CAP-accredited laboratory, its microRNA-based platform for brain-enriched and inflammation-associated biomarkers, and its focus on brain health and neurodegenerative diseases.
In addition, Aptorum’s news releases describe financing transactions, including registered direct offerings of Class A ordinary shares and concurrent private placements of warrants, with stated uses of proceeds that include funding expenses related to the proposed merger and general working capital. Other announcements address Nasdaq listing matters, such as receipt of a minimum bid price deficiency notice and subsequent regaining of compliance with Nasdaq’s minimum bid price requirement.
Investors and observers following APM news can therefore expect updates on the progress of the proposed merger with DiamiR, scientific and regulatory developments connected to DiamiR’s diagnostics portfolio, Aptorum’s financing activities, and disclosures related to its Nasdaq listing status and SEC filings. The news stream collectively provides insight into how Aptorum presents its evolving strategy across oncology, infectious diseases, and, through the planned merger, brain health-focused diagnostics.
Aptorum Group Limited (Nasdaq: APM) announced a special extraordinary meeting of shareholders on February 21, 2023, at its London office. The meeting will address proposals for a merger with a newly established subsidiary and a reduction in share par value from USD10 to USD0.00001. These changes aim to streamline company structure and improve capital efficiency. Details are available in a Form 6-K filed with the SEC on February 6, 2023. Aptorum is focused on the development of therapeutics for unmet medical needs, particularly in oncology, autoimmune diseases, and infectious diseases.
Aptorum Group Limited (NASDAQ: APM) announced a 1-for-10 reverse stock split effective January 23, 2023, approved by shareholders on December 21, 2022. The Company aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share by ensuring that its Class A Ordinary Shares maintain this price for at least 10 consecutive business days before May 16, 2023. The reverse split consolidates every 10 shares into 1, affecting both Class A and Class B shares. The new CUSIP number for Class A shares post-split is G6096M 114.
Aptorum Group Limited (Nasdaq: APM) has published a paper detailing a rapid low-depth unbiased metagenomics sequencing workflow for diagnosing infectious diseases using the PathsDx Test. This test achieved over 95% sensitivity and specificity, with 93% agreement with standard diagnostic tests. The paper emphasizes the versatility of Illumina platforms in detecting DNA and RNA pathogens. With a growing genomic database of nearly 20,000 species, Aptorum is expanding validation sites in Singapore, Hong Kong, and the U.S. to enhance its testing capabilities.
Aptorum Group Limited (Nasdaq: APM) held its 2022 annual general meeting on December 21, 2022, in London. Shareholders re-elected seven directors and confirmed the re-appointment of Marcum Asia CPAs LLP as independent auditors. A significant decision made was the approval of a share consolidation, where every 10 Class A Ordinary Shares will convert to 1 Class A Share, and the same ratio applies for Class B Ordinary Shares, effective before December 21, 2023. Following this consolidation, the authorized share capital will be $100,000,000 divided into 6 million Class A shares and 4 million Class B shares.
Aptorum Group Limited (NASDAQ: APM) has completed a private offering of USD $3 million in convertible notes due December 2023. The offering, subscribed by Aenco Technologies Limited, is aimed at supporting daily operations and clinical programs. The notes, which carry a 7% annual interest rate and a conversion price of $1.20 per share, are to be utilized primarily for R&D of therapeutic candidates and commercialization of its health products. This financing reflects strong insider support for Aptorum's strategic initiatives.
Aptorum Group Limited (Nasdaq: APM) announced a private offering of USD$3 million convertible notes due 2023. These notes, secured solely by Aenco Technologies Limited, will support daily operations and clinical programs. They carry a 7% interest rate and convert at $1.20 per share. The proceeds will fund R&D of candidates like SACT-1 and ALS-4, and the commercialization of the NativusWell® product. This offering reflects strong insider support and is exempt from SEC registration.
Aptorum Group Limited (NASDAQ: APM) will be featured in an interview on The RedChip Money Report airing on Bloomberg TV on November 26, 2022, at 7 p.m. ET. CEO Darren Lui will discuss Aptorum's pipeline targeting oncology, autoimmune, and infectious diseases, highlighting a $15 billion market opportunity and the completion of Phase 1 trials. The interview can be accessed at this link.
Aptorum Group Limited (NASDAQ: APM) announces the publication of a validated analytical method for measuring plasma pro-EGCG and its metabolites. Developed in collaboration with The Chinese University of Hong Kong, the method uses ultra-performance liquid chromatography and is crucial for in vivo pharmacokinetic studies. The company aims to utilize this assay for future Phase 1 clinical trials of Pro-EGCG, targeting endometriosis, which affects approximately 10% of women of reproductive age according to WHO.
Aptorum Group Limited (NASDAQ: APM) received a deficiency letter from Nasdaq due to its Class A Ordinary Shares trading below the $1.00 minimum bid price for 30 straight business days. The company has until May 16, 2023 to regain compliance. If the share price meets the required threshold for 10 consecutive business days before this date, Nasdaq will confirm compliance. Should compliance not be achieved, Aptorum may apply for an extension, including the option of a reverse stock split to remedy the deficiency.
Aptorum Group Limited (NASDAQ: APM) will hold its 2022 annual general meeting on December 21, 2022, at its London office. Shareholders as of October 14, 2022, can vote and receive notice for the meeting. The company filed its annual report on Form 20-F, including audited financials for the fiscal year ending December 31, 2021, with the SEC on April 29, 2022. Aptorum focuses on developing therapeutics for oncology and infectious diseases, having completed two Phase I clinical trials. For more details, visit their website.